Patents by Inventor Shlomit REICH-ZELIGER

Shlomit REICH-ZELIGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetically modified veto cells and use of same in immunotherapy
    Patent number: 11555178
    Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 17, 2023
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Esther Bachar-Lustig, Shlomit Reich-Zeliger
  • IDENTIFICATION OF RECURRENT MUTATED NEOPEPTIDES
    Publication number: 20220241331
    Abstract: A method of treating cancer in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of T cells expressing a T cell receptor (TCR) having a CDR3 amino acid sequence selected from the group consisting of 199-210.
    Type: Application
    Filed: May 19, 2020
    Publication date: August 4, 2022
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yardena SAMUELS, Shelly KALAORA, Aviyah PERI, Nir FRIEDMAN, Shlomit REICH-ZELIGER, Erez GREENSTEIN
  • Methods of transplantation and disease treatment
    Patent number: 10751368
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 25, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Esther Bachar-Lustig, Shlomit Reich-Zeliger
  • GENETICALLY MODIFIED VETO CELLS AND USE OF SAME IN IMMUNOTHERAPY
    Publication number: 20190338247
    Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.
    Type: Application
    Filed: January 18, 2018
    Publication date: November 7, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Esther BACHAR-LUSTIG, Shlomit REICH-ZELIGER
  • METHODS OF TRANSPLANTATION AND DISEASE TREATMENT
    Publication number: 20180200300
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 19, 2018
    Inventors: Yair REISNER, Esther BACHAR-LUSTIG, Shlomit REICH-ZELIGER
  • T-CELL RECEPTOR CDR3 PEPTIDES AND ANTIBODIES
    Publication number: 20170174764
    Abstract: The present invention provides isolated peptides derived from TCR CDR3 segments, antibodies which recognize them, pharmaceutical compositions comprising them and methods of their use for modulating self-immunity.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Inventors: Irun R. COHEN, Nir FRIEDMAN, Asaf MADI, Eric SHIFRUT, Shlomit REICH-ZELIGER, Asaf PORAN